4-(氯甲基)-2-甲基喹啉盐酸盐 | 252919-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-(氯甲基)-2-甲基喹啉盐酸盐
• 英文名称: 4-chloromethyl-2-methylquinoline hydrochloride
• 英文别名: 4-(chloromethyl)-2-methylquinoline;hydrochloride
• CAS: 252919-32-7
• 化学式: C₁₁H₁₀ClN*ClH
• 分子量: 228.121
• InChiKey: NFXFTRUTNFGBFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(氯甲基)-2-甲基喹啉盐酸盐 在 盐酸 、 sodium hydroxide 、 羟胺 、 甲基磺酰氯 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 4-[2-Hydroxyamino-3-{4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl}propyliden]cyclohexanone
  参考文献：
  名称：

  Reverse hydroxamate-based selective TACE inhibitors

  摘要：

  Reverse hydroxamate-based selective TACE inhibitors are described. They have potent TACE inhibitory activities and excellent selectivities against MMP-1, 2, 3, 8, 9, 13, 14, and 17. One representative compound, 18 has demonstrated an excellent oral inhibitory activity of the lipopolysaccharide (LPS)-stimulated TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.048
• 作为产物：
  描述：

  2-甲基喹啉-4-甲酸 在 氯化亚砜 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 21.5h， 生成 4-(氯甲基)-2-甲基喹啉盐酸盐
  参考文献：
  名称：

  Development of a Suitable Process for the Preparation of a TNF-α Converting Enzyme Inhibitor, WAY-281418

  摘要：

  A suitable process for the preparation of kilogram quantities of a TNF-alpha converting enzyme (TACE) inhibitor (WAY-281418) was developed using isatin 13 as starting material and an efficient coupling step for the formation of sulfonamide 8 in a 15% overall yield. Process preparation of (+)-(1S,2R)-2-aminocyclopentane-1-carboxylic acid (7, (+)-cispentacin), a chiral component for WAY-281418, was successfully scaled up via an asymmetric hydrogenation reaction. Crystallization allowed the isolation of all intermediates and the final product 9.

  DOI：

  10.1021/op800090s

文献信息

• Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha
  申请人：——

  公开号：US20020013341A1

  公开（公告）日：2002-01-31

  The present application describes novel &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, U a , X a , Y a , Z a , R 1 , R 2 , R 3 , R 4 , and R 4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.

  本申请描述了式I的新型β-氨基酸衍生物： 1 或其药用可接受的盐或前药形式，其中A、X、Z、U a 、X a 、Y a 、Z a 、R 1 、R 2 、R 3 、R 4 和R 4a 在本规范中有定义，这些衍生物可用作金属蛋白酶和/或TNF-α抑制剂。
• Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis
  作者：Jean-Guy Boiteau、Gilles Ouvry、Jean-Marie Arlabosse、Stéphanie Astri、Audrey Beillard、Yushma Bhurruth-Alcor、Laetitia Bonnary、Claire Bouix-Peter、Karine Bouquet、Marilyne Bourotte、Isabelle Cardinaud、Catherine Comino、Benoît Deprez、Denis Duvert、Angélique Féret、Feriel Hacini-Rachinel、Craig S. Harris、Anne-Pascale Luzy、Arnaud Mathieu、Corinne Millois、Nicolas Orsini、Jonathan Pascau、Artur Pinto、David Piwnica、Gaëlle Polge、Arnaud Reitz、Kevin Reversé、Nicolas Rodeville、Patricia Rossio、Delphine Spiesse、Samuel Tabet、Nathalie Taquet、Loïc Tomas、Emmanuel Vial、Laurent F. Hennequin

  DOI：10.1016/j.bmc.2017.07.054

  日期：2018.2

  in-house research programs. In this article, we present the discovery of clinical candidate 26a. Starting from hits plagued with poor solubility or genotoxicity, 26a was identified through thorough multiparameter optimisation. Showing robust in vivo activity in an oxazolone-mediated inflammation model, the compound was selected for development. Following a polymorph screen, the hydrochloride salt was

  靶向TNFα途径是治疗牛皮癣的有效方法。在这一途径中，TACE成为可药物治疗的目标，并且一直是内部研究计划的重点。在本文中，我们介绍了临床候选药物26a的发现。从溶解度或基因毒性差的命中开始，通过彻底的多参数优化确定了26a。在恶唑酮介导的炎症模型中显示出强大的体内活性，因此选择了该化合物进行开发。经过多晶型物筛选后，选择盐酸盐，并有效地进行了合成，以API的总收率达到47％。
• [EN] N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS<br/>[FR] COMPOSÉS DE N-[2-HYDROXYCARBAMOYL-2-(PIPÉRAZINYL)ÉTHYL]BENZAMIDE, LEUR PRÉPARATION ET UTILISATION À TITRE D'INHIBITEURS DE TACE
  申请人：GALDERMA RES & DEV

  公开号：WO2011033009A1

  公开（公告）日：2011-03-24

  The present invention relates to novel benzene-carboxamide compounds having a structure that corresponds to the general formula (I), and also to their method of synthesis and to their use in pharmaceutical compositions intended for use in human or veterinary medicine or else to their use in cosmetic compositions.

  本发明涉及具有与通式（I）对应的结构的新型苯甲酰胺化合物，以及它们的合成方法，以及它们在用于人类或兽医药物的制剂中的使用，或者在化妆品组合物中的使用。
• NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS
  申请人：Clary Laurence

  公开号：US20120323006A1

  公开（公告）日：2012-12-20

  Benzenesulfonamide compounds having a structure of formula (I) are described. Also described, are methods for synthesizing the compounds and to the use thereof in pharmaceutical compositions for human or veterinary medicine and in cosmetic compositions.

  描述了具有结构式（I）的苯磺酰胺化合物。还描述了合成这些化合物的方法，以及将其用于人类或兽医药物和化妆品组合物中的用途。
• Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
  申请人：Levin I. Jeremy

  公开号：US20060211730A1

  公开（公告）日：2006-09-21

  This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.

  这项发明提供了具有结构的Formula I的化合物，这些化合物在治疗由TNF-α介导的疾病或紊乱方面非常有用，如关节炎（类风湿关节炎（RA），幼年RA，银屑病性关节炎，骨关节炎等），肿瘤转移，组织溃疡，异常伤口愈合，牙周病，骨病，糖尿病（胰岛素抵抗）和HIV感染，强直性脊柱炎，银屑病，败血症，多发性硬化，克罗恩病，退行性软骨丢失，哮喘，特发性肺纤维化，血管炎，系统性红斑狼疮，肠易激综合征，急性冠状动脉综合征，丙型肝炎，虚弱，慢性阻塞性肺病，中风或2型糖尿病的缓解症状。该发明还提供了使用这些化合物的方法。